Jim Cramer on Becton, Dickinson: "I Kind of Really Like the New Company"

Becton, Dickinson and Company (NYSE:BDX) is one of the stocks in focus on Jim Cramer’s game plan. Cramer showed bullish sentiment toward the company, as he said:

Now, there’s been some incredible moves happening in the medical devices distribution space this quarter. The once unsinkable Boston Scientific got clobbered this week because the competition got intense in their pulse field ablation business, which they had dominated. But on the other side, I told you that McKesson last week could be counted on for an upside surprise of gigantic proportions, and I have praised Cardinal Health to the moon multiple times.

Well, McKesson and Cardinal Health both shot the lights out. These are classic drug middlemen. You can buy them anytime they’re down. Although the problem is they’re almost never down. Well, the next device company that reports is called BD. Now, that’s the old Becton, Dickinson. It’s streamlined the business, and I kind of really like the new company. I expect a very positive forecast.

Becton, Dickinson and Company (NYSE:BDX) sells a significant variety of medical supplies, diagnostic tools, and lab equipment used by healthcare professionals and researchers.

While we acknowledge the potential of BDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.